CN103316330A - 一种软组织创伤护理材料的组方与用途 - Google Patents
一种软组织创伤护理材料的组方与用途 Download PDFInfo
- Publication number
- CN103316330A CN103316330A CN2013102039779A CN201310203977A CN103316330A CN 103316330 A CN103316330 A CN 103316330A CN 2013102039779 A CN2013102039779 A CN 2013102039779A CN 201310203977 A CN201310203977 A CN 201310203977A CN 103316330 A CN103316330 A CN 103316330A
- Authority
- CN
- China
- Prior art keywords
- polylysine
- epsilon
- purposes
- tissue trauma
- collagen protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000014674 injury Diseases 0.000 title claims abstract description 20
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 20
- 230000008733 trauma Effects 0.000 title claims abstract description 20
- 239000000463 material Substances 0.000 title claims abstract description 18
- 230000000474 nursing effect Effects 0.000 title claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 34
- 108010035532 Collagen Proteins 0.000 claims abstract description 34
- 108010039918 Polylysine Proteins 0.000 claims abstract description 25
- 206010048038 Wound infection Diseases 0.000 claims abstract description 5
- 230000008470 skin growth Effects 0.000 claims abstract description 4
- 206010052428 Wound Diseases 0.000 claims description 14
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- 210000000589 cicatrix Anatomy 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 2
- 230000029663 wound healing Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
- 229940012189 methyl orange Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001363490 Monilia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048031 Wound dehiscence Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- STZCRXQWRGQSJD-UHFFFAOYSA-M sodium;4-[[4-(dimethylamino)phenyl]diazenyl]benzenesulfonate Chemical compound [Na+].C1=CC(N(C)C)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
名称 | 型号 | 生产厂家 |
紫外光栅分光光度计 | 752 | 上海精密科学仪器有限公司. |
高效液相色谱仪 | LC-15C | 日本岛津制作所 |
离心机 | 80-2 | 江苏省金坛市荣华仪器制造有限公司 |
电热恒温水浴锅 | ---- | 天津泰斯特仪器有限公司 |
电热恒温鼓风干燥箱 | 立鹤牌 | 山东潍坊精鹰医疗器械有限公司 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310203977.9A CN103316330B (zh) | 2012-06-28 | 2013-05-21 | 一种软组织创伤护理材料的组方与用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102304835 | 2012-06-28 | ||
CN201210230483.5 | 2012-06-28 | ||
CN201210230483 | 2012-06-28 | ||
CN201310203977.9A CN103316330B (zh) | 2012-06-28 | 2013-05-21 | 一种软组织创伤护理材料的组方与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103316330A true CN103316330A (zh) | 2013-09-25 |
CN103316330B CN103316330B (zh) | 2016-03-09 |
Family
ID=49185562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310203977.9A Active CN103316330B (zh) | 2012-06-28 | 2013-05-21 | 一种软组织创伤护理材料的组方与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103316330B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160120936A1 (en) * | 2014-10-30 | 2016-05-05 | Karen Troxel | Methods of preventing surgical site infections |
CN110772662A (zh) * | 2019-11-30 | 2020-02-11 | 山东百多安医疗器械有限公司 | 一种抗菌膨体聚四氟乙烯面部植入材料及其制备工艺 |
CN113164512A (zh) * | 2018-11-26 | 2021-07-23 | 韩国海洋科学技术院 | 刺激脂肪生成的肽、组合物和方法 |
CN114983991A (zh) * | 2022-05-30 | 2022-09-02 | 浙江大学 | 一种兼具抗炎及抗氧化作用的药物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1471412A (zh) * | 2000-06-29 | 2004-01-28 | ����ϳɼ������ô�˾ | 用于修复和再生软骨和其它组织的组合物和方法 |
EP2210917A1 (en) * | 2007-11-01 | 2010-07-28 | Osaka City University | -1,3-glucan-derived polyaldehyde/polyamine hydrogel |
CN102028705A (zh) * | 2010-11-01 | 2011-04-27 | 西藏贝珠雅药业有限公司 | 一种含生物抑菌成分的妇科用品 |
CN102228716A (zh) * | 2011-06-25 | 2011-11-02 | 四川大学 | 一种胶原蛋白-pcl牙科止血海绵及其制备方法 |
-
2013
- 2013-05-21 CN CN201310203977.9A patent/CN103316330B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1471412A (zh) * | 2000-06-29 | 2004-01-28 | ����ϳɼ������ô�˾ | 用于修复和再生软骨和其它组织的组合物和方法 |
EP2210917A1 (en) * | 2007-11-01 | 2010-07-28 | Osaka City University | -1,3-glucan-derived polyaldehyde/polyamine hydrogel |
CN102028705A (zh) * | 2010-11-01 | 2011-04-27 | 西藏贝珠雅药业有限公司 | 一种含生物抑菌成分的妇科用品 |
CN102228716A (zh) * | 2011-06-25 | 2011-11-02 | 四川大学 | 一种胶原蛋白-pcl牙科止血海绵及其制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160120936A1 (en) * | 2014-10-30 | 2016-05-05 | Karen Troxel | Methods of preventing surgical site infections |
WO2016070046A1 (en) * | 2014-10-30 | 2016-05-06 | Karen Troxel | Methods of preventing surgical site infections |
AU2015338969B2 (en) * | 2014-10-30 | 2020-08-27 | Biomet Manufacturing, Llc | Methods of preventing surgical site infections |
CN113164512A (zh) * | 2018-11-26 | 2021-07-23 | 韩国海洋科学技术院 | 刺激脂肪生成的肽、组合物和方法 |
CN110772662A (zh) * | 2019-11-30 | 2020-02-11 | 山东百多安医疗器械有限公司 | 一种抗菌膨体聚四氟乙烯面部植入材料及其制备工艺 |
CN114983991A (zh) * | 2022-05-30 | 2022-09-02 | 浙江大学 | 一种兼具抗炎及抗氧化作用的药物 |
CN114983991B (zh) * | 2022-05-30 | 2024-03-12 | 浙江大学 | 一种兼具抗炎及抗氧化作用的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN103316330B (zh) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103356692B (zh) | 一种复合抗菌凝胶剂及其制备方法 | |
CN103316330B (zh) | 一种软组织创伤护理材料的组方与用途 | |
CN100379465C (zh) | 一种消炎、止痛、抗菌的可溶性止血纱布 | |
WO2006079288A1 (fr) | Emploi de lysozyme humaine dans la préparation de produits cosmétiques contre l'acné | |
CN113599506B (zh) | 一种铂纳米酶/葡萄糖氧化酶@透明质酸复合抗菌材料及其制备和应用 | |
Song et al. | Chitosan/poly (3-hydroxy butyric acid-co-3-hydroxy valeric acid) electrospun nanofibers with cephradine for superficial incisional skin wound infection management | |
CN101475920B (zh) | 一种治疗烧伤的短小芽孢杆菌及其代谢产物的制备方法 | |
Pedro et al. | Switchable adhesive films of pullulan loaded with a deep eutectic solvent-curcumin formulation for the photodynamic treatment of drug-resistant skin infections | |
CN108403676B (zh) | 琥珀酸在提高细菌对抗生素敏感性方面的应用 | |
CN109200326A (zh) | 用于伤口愈合的敷料及创口贴 | |
CN100379464C (zh) | 一种消炎、抗菌镇痛的可溶性止血纱布及其加工方法 | |
CN105749326B (zh) | 一种多肽抗菌自组装复合材料及其制备方法 | |
CN101618025B (zh) | 一种兽用盐酸多西环素冻干制剂及其制备方法 | |
CN102370649B (zh) | 一种抑制细菌信号转导系统YycG组氨酸激酶活性的制剂 | |
CN105560374A (zh) | 一种用于治疗奶牛乳腺炎的复方制剂及其制备方法 | |
CN102886054B (zh) | 一种抑制细菌信号转导系统PhoQ组氨酸激酶活性的制剂 | |
Basir et al. | Antibacterial activity test of Moringa leaf ethanol extract ointment of Moringa oleifera Lamk. on Staphylococcus aureus bacteria | |
CN116035001B (zh) | 一种白葡萄球菌灭活剂及灭活方法 | |
CN114159337B (zh) | 一种含重组人溶菌酶的面部抗菌护理液 | |
CN105232540A (zh) | 一种治疗烧伤后感染的药物组合物 | |
RU2401116C2 (ru) | Ранозаживляющий пробиотический препарат | |
Brkich et al. | Pharmaceutical Composition Based on Two Innovative Chitosan-Containing Substances–The Chitosan-Chymopsin Complex and the Chitosan-Miramistin Complex–for Production of a Finished Dosage Form for the Treatment of Infected Wounds of Various Origins | |
CN105622619A (zh) | 一种治疗牙周炎的药物组合物 | |
CN105232542B (zh) | 一种治疗小儿肺炎的药物组合物 | |
CN105287478B (zh) | 一种治疗胃炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone No. 15 Patentee after: TIBET BEIZHUYA PHARMACEUTICAL Co.,Ltd. Address before: 852000 No. 39 South Lhasa Road, Nagqu Town, Nagchu Prefecture, Tibet Autonomous Region Patentee before: TIBET BEIZHUYA PHARMACEUTICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Ba Sangciren Document name: Notice of Qualified Procedures |
|
DD01 | Delivery of document by public notice | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240221 Address after: 850000 Yajiang Industrial Park, Qushui County, Lhasa, Xizang Autonomous Region Patentee after: Tibet Bezhuya Pharmaceutical (Group) Co.,Ltd. Country or region after: China Address before: No. 15, Linqionggang Road, Lhasa Economic and Technological Development Zone, Xizang Autonomous Region, 850000 Patentee before: TIBET BEIZHUYA PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |